Announcement of UPDATES to New Medicine-Oncology KnowledgeBase Data Base for September 2014
October 29, 2014 by 2012pharmaceutical
Announcement of UPDATES to New Medicine-Oncology KnowledgeBase Data Base for September 2014
Curator: Katie Siafaca
Latest Updates
September 2014 New Drug Updates and Additions
Designation |
Brand Name |
Generic Name |
OncoVEX GM-CSF, OncoVEXGMCSF, OncoVEXGM-CSF, Tvec, t-vec |
|
Talimogene laherparepvec |
IL-17E |
|
|
BIBF 1120 |
Vargatef |
Nintedanib |
CV9202 |
|
|
CV9104 |
|
|
EPZ005687, EPZ-6438, E7438 |
|
|
EPZ-5676, EPZ004777 |
|
|
RG3638, anti-c-Met, PRO143966, RO5490258 |
MetMab |
Onartuzumab |
G-202 |
|
Mipsagargin |
AB0024, GS-6624 |
|
Simtuzumab |
GS-5745 |
|
|
PEGPH20 |
|
|
L-DOS47 |
|
|
IPI-145 |
|
Duvelisib |
KTN3379 |
|
|
5B1 |
|
|
MEDI4736 |
|
|
L-BLP25, BLP-25 (formerly BP1-7-KLH), EMD531444, emepepimut-S |
Formerly Stimuvax |
Tecemotide |
MSB0010718C |
|
|
MM-121, MM121, SAR256212 |
|
|
PEP02, MM-398, nal-IRI |
|
|
CRA-024781, CG-781, PCI-24781, S-78454 |
|
Abexinostat |
RX-3117 |
|
|
TG4010, MVA-MUC-1-IL-2, MVA-MUC1-IL-2 |
|
|
|
September 2014 Marketed Drug Updates and Additions
Brand Name |
Generic Name |
Other Designation |
Pixuvri |
Pixantrone dimaleate |
BBR 2778 |
Cyramza |
Ramucirumab |
IMC-1121b, IMC 1121B, LY3009806 |
Perjeta (formerly Omnitarg) |
Pertuzumab |
RG1273, R1273, 2C4, rhuMAb-2C4 |
Zydelig |
Idelalisib |
CAL-101, GS-1101 |
Keytruda |
Pembrolizumab (formerly lambrolizumab) |
MK-3475 |
Lymphoseek |
Technetium Tc 99m tilmanocept |
|
Zykadia |
Ceritinib |
LDK378 |
Afinitor |
Everolimus |
RAD001, RAD001C |
Zelboraf |
Vemurafenib |
PLX4032, PLX4720, RG7204, RO5185426 |
|
September 2014 Company Updates and Additions
- AADi
- Abcodia
- Accelovance
- Adimab
- Affymax
- Akinion Pharmaceuticals
- Aprea
- Aptose Biosciences
- BeiGene
- Bioceros
- Biogen Idec
- Blueprint Medicines
- BTG
- Can-Fite BioPharma
- Caris Life Sciences
- Celgene
- Cellerant Therapeutics
- Champions Oncology
- CureVac
- DanDrit Biotech
- Epizyme
- Eutropics Pharmaceuticals
- F2G
- Genetic Technologies
- Ignyta
- ImaginAb
|
- Johnson & Johnson (J&J)
- Karolinska Development
- Kolltan Pharmaceuticals
- Lpath
- Merus
- Novartis
- OncoCyte
- Oncology Analytics (OA)
- OncoNOx
- Oncothyreon
- Personal Genome Diagnostics (PGDx)
- ProNAi Therapeutics
- Propanc Health Group
- Protagonist Therapeutics
- Regeneron Pharmaceuticals
- Relmada Therapeutics
- Rosetta Genomics
- Scholar Rock
- Sentinel Oncology
- Sevion Therapeutics
- SutroVax
- to-BBB Technologies (to-BBB)
- Transgene
- Veracyte
- Zenith Epigenetics
|
September 2014 Targets in Oncology Updates and Additions
- Fibroblast growth factor receptor 4 (FGFr4)
- KIT
- MUC16
- V-raf murine sarcoma viral oncogene homolog B1 (BRAF)
|
SOURCE
http://www.nmok.net/oksite/updates.html
From: info <info@newmedinc.com>
Reply-To: <info@newmedinc.com>
Date: Wed, 29 Oct 2014 13:41:44 -0700
To: “Aviva Lev-Ari, PhD, RN” <avivalev-ari@alum.berkeley.edu>
Subject: DB coverage
Like this:
Like Loading...
Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, FDA, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Pharmacodynamics and Pharmacokinetics, Pharmacogenomics, Pharmacologic toxicities, Regulated Clinical Trials: Design, Methods, Components and IRB related issues | Leave a Comment
Leave a Reply